

## **Supplementary document**



**Figure S1.** Principal component analysis (PCA) biplots of RNA-seq samples from color-coded groups (related to **Figure 2**). Yellow boxes indicate combination of principal components that can distinguish two groups.



**Figure S2**. Relative mRNA levels of 2 genes as reported in normal lung and lung cancer tissues (related to **Figure 2**).






Figure S3. Differential gene expression meta-analysis on annotated genes (related to Figure 3).





CD4 T cells

0.66

063

0.68 0.78 0.65 0.63 0.64

83 0.78 0.84 0.91

RCAN

TCEAS

ORCI

CD28

PASK

0.72 0.85


087 1

0.72

72 076 094 069 097 053 094 052 053

091 0.95 0.01 0.0

0.74 0.72



0.76 0.84 0.8 0.77 0.77

0019 22


VPREB3

BANKI

09 0.97

12

**Figure S4.** Pairwise similarity of filtered marker genes in 7 cell subsets as finalized in the updated AImmune approach. Pairwise similarity was computed based on gene expression across all subjects. DCs, dendritic cells.



**Figure S5.** Immune cell scores of 5 cell subsets produced by Monte Carlo simulation (n=20 v 20), utilizing original leukocyte scores produced by from res and non-res subjects.

Supplemental Table S1 DEG lists identified from this study

Table S1a List of DEGs identified by comparison of post- versus pre- treatment

Table S1b List of DEGs identified by comparison of responders versus non-responders

Supplemental Table S2 Summary of validation results

 Table S2a Validation summary of top 10 DEGs identified by comparison of post- versus

 pre- treatment

 Table S2b
 Validation summary of top 10 DEGs identified by comparison of responders

 versus non-responders

Supplemental Table S3 List of PCR primers used in this study